Company Filing History:
Years Active: 2012-2013
Title: Innovations by Jane Far-Jine Djung
Introduction
Jane Far-Jine Djung is an accomplished inventor based in Furlong, PA (US). She has made significant contributions to the field of pharmaceuticals, particularly in the development of inhibitors for Protein Kinase C-alpha (PKC-α). With a total of 2 patents, her work focuses on improving myocardial function and addressing heart failure.
Latest Patents
Jane's latest patents include two notable inventions. The first patent, titled "2-anilino-4-(heterocyclic)amino-pyrimidines," relates to inhibitors that target Protein Kinase C-alpha (PKC-α). These inhibitors are crucial for enhancing myocardial intracellular calcium cycling, which leads to improved myocardial contraction and relaxation performance, ultimately slowing the progression of heart failure. The second patent, "2-anilino-4-aminoalkyleneaminopyrimidines," also focuses on PKC-α inhibitors. This invention aims to control and abate the progression of heart failure through similar mechanisms.
Career Highlights
Jane is currently employed at Boehringer Ingelheim International GmbH, where she continues to innovate in the pharmaceutical industry. Her work has garnered attention for its potential impact on heart health and treatment options for heart failure.
Collaborations
Throughout her career, Jane has collaborated with notable colleagues, including Adam A Golebiowski and Jack A Hunter. These partnerships have contributed to her success and the advancement of her research.
Conclusion
Jane Far-Jine Djung is a pioneering inventor whose work in developing PKC-α inhibitors is making strides in the fight against heart failure. Her contributions to the field are significant and continue to inspire advancements in pharmaceutical research.